HOME >> BIOLOGY >> NEWS
Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute

us drawbacks.

The enzyme has to be infused intravenously or through a surgically implanted catheter--usually in a doctor's office--a process that takes several hours and must be repeated every one or two weeks. Enzyme replacement therapy is also extremely expensive, costing between $100,000 and $750,000 per year per patient. And the therapy is not effective at treating neurological complications of Gaucher disease.

Now Kelly, Beutler, and their colleagues at TSRI report positive results on a radically different approach that may address some of the problems with enzyme replacement therapy. Rather than replacing the mutant enzyme, says Kelly, "We use a small molecule to partially correct [its] imperfections."

Their small molecule "chaperone" stabilizes the mutant beta-glucosidase enzyme, helping it to fold properly and find its way to the lysosome, where it can degrade the fatty substance.

The chaperone targets the most common Gaucher mutation, which is referred to as "1226G" or "N370S." Virtually every Jewish patient with Gaucher disease has this beta-glucosidase mutation.

A therapy based on these chaperones has the potential to be much more convenient and less costly than enzyme replacement, because small molecules could be taken orally and would be cheaper to mass-produce than whole enzymes. In addition, small molecules can be found that cross the blood-brain barrier, and perhaps address the neurological complications of Gaucher disease, if they are caused by mutants that respond to chaperone therapy.

The article, "Chemical chaperones increase the cellular activity of N370S beta-glucosidase: A therapeutic strategy for Gaucher disease" was authored by Anu R. Sawkar, Wei-Chieh Cheng, Ernest Beutler, Chi-Huey Wong, William E. Balch, and Jeffrey W. Kelly, and appears in the online edition of the journal Proceedings of the National Academy of Sciences the week of November 4, 2002. The article will appear in print la
'"/>

Contact: Jason Bardi
jbardi@scripps.edu
858-784-9254
Scripps Research Institute
4-Nov-2002


Page: 1 2 3 4

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential blood test for colon cancer risk
3. Potential cause of arthritis discovered
4. Potential of regenerative medicine explored
5. Potential therapy reported for children, adults with end-stage liver disease
6. Potential allergy vaccine boosts hope for sufferers
7. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
8. Potential new anthrax therapy discovered
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics ... recognition and multiple awards for not only the products and treatments developed, but ... and Vivace® Microneedle RF. All the brands built by ABM have received several ...
(Date:7/2/2020)... Md. (PRWEB) , ... July ... ... Molecular Biology Systems, B.V. (MBS) has announced a publication detailing the use ... one-step reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a ... most common and aggressive adult brain cancer—announced today the appointments of its first ... charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows are ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... 29, 2020 , ... G-CON Manufacturing, the leader in off-site ... FOR LIFE.” The adoption of this taglines comes at a time of tremendous ... to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. G-CON’s ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/18/2020)... Ohio (PRWEB) , ... July 16, 2020 , ... ... data solutions to aid in the early detection and prevention of high-burden diseases, ... to enable US-based hospitals and healthcare organizations to utilize existing data in order ...
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
Breaking Biology Technology:
Cached News: